{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:10:31Z","timestamp":1789726231550,"version":"4.0.1"},"reference-count":79,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"45","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease associated with liver inflammation, fibrosis, and cirrhosis and is associated with a greater risk of hepatocarcinoma. Nonalcoholic steatohepatitis (NASH) is a persistent and progressive form of NAFLD. Recent evidence suggested that ertugliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2), suppresses NAFLD development in patients with type 2 diabetes mellitus (T2DM). The objective of this study was to determine the impact of ertugliflozin on improving NAFLD in patients with T2DM and the function of liver enzymes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This prospective, randomized, double-blind, placebo-controlled, interventional study aimed to determine the effectiveness of 15\u2009mg of ertugliflozin versus 30\u2009mg of the standard therapy pioglitazone versus placebo in NAFLD patients with T2DM. The study was established based on patient randomization in three groups: ertugliflozin, pioglitazone, and a placebo. This study was registered under the Australian New Zealand Clinical Trial Registry (Trial ID: ACTRN12624000032550).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The impact of therapy was determined in the treatment groups by utilizing liver ultrasonography and biochemical parameters. After 24 weeks of clinical study, the results revealed significant improvement in the grades of fatty liver, especially in the ertugliflozin group. The number of patients with hepatic steatosis significantly decreased among the respective groups classified according to fatty liver grade. Among patients in the ertugliflozin and pioglitazone groups, 45% to 23.4% and 41.7% to 26.6%, respectively, decreased in the Grade 2 group. The aspartate aminotransferase and alanine aminotransferase levels were significantly lower in all the study groups, especially in the ertugliflozin group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005\u2264\u2005.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The present study revealed that the concomitant use of ertugliflozin has favorable effects on liver enzymes, as it decreases liver fat intake and reduces complications in patients with NAFLD-associated T2DM. However, more in-depth studies will be required to observe every aspect of ertugliflozin.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000040356","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T20:01:35Z","timestamp":1731355295000},"page":"e40356","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: A randomized controlled trial"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3887-5980","authenticated-orcid":false,"given":"Adil","family":"Khaliq","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Abdul Wali Khan University Mardan, Mardan, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroon","family":"Badshah","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Abdul Wali Khan University Mardan, Mardan, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasar","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Abdul Wali Khan University Mardan, Mardan, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inayat Ur","family":"Rehman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Abdul Wali Khan University Mardan, Mardan, Pakistan"},{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Universiti Malaya, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashif Ullah","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Universiti Malaya, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long Chiau","family":"Ming","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, School of Medical and Life Sciences, Sunway University, Bandar Sunway, Malaysia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maong Hui","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, School of Medical and Life Sciences, Sunway University, Bandar Sunway, Malaysia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"e0286586","DOI":"10.1371\/journal.pone.0286586","article-title":"Clinical epidemiology of non-alcoholic fatty liver disease in children and adolescents. The LiverKids: study protocol.","volume":"18","author":"Chacon","year":"2023","journal-title":"PLoS One"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"129","DOI":"10.14744\/hf.2023.2023.0032","article-title":"Prevalence and predictors of metabolic-associated fatty liver disease in liver transplant recipients: a cross-sectional prospective study.","volume":"4","author":"Adali","year":"2023","journal-title":"Hepatol Forum"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"430","DOI":"10.5603\/ep.95686","article-title":"Choroidal vascular changes in non-alcoholic fatty liver disease.","volume":"74","author":"Avci","year":"2023","journal-title":"Endokrynol Pol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.2147\/DMSO.S430740","article-title":"The impact of intermittent fasting on non-alcoholic fatty liver disease in older adults: a review of clinicaltrials.gov registry.","volume":"16","author":"Alorfi","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1097\/j.pbj.0000000000000228","article-title":"Impact of obesity on liver function tests: is nonalcoholic fatty liver disease the only player? A review article.","volume":"8","author":"El-Eshmawy","year":"2023","journal-title":"Porto Biomed J"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"e1913","DOI":"10.1002\/cnr2.1913","article-title":"Associations of non-alcoholic fatty liver disease and cirrhosis with liver cancer in European and East Asian populations: a Mendelian randomization study.","volume":"7","author":"Deng","year":"2023","journal-title":"Cancer Rep (Hoboken)"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1097\/MEG.0000000000002654","article-title":"Unveiling the role of gut dysbiosis in non-alcoholic fatty liver disease.","volume":"35","author":"Jadhav","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2337\/dc16-1787","article-title":"Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action.","volume":"40","author":"Bril","year":"2017","journal-title":"Diabetes Care"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis.","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s12072-024-10661-x","article-title":"MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD.","volume":"18","author":"Chan","year":"2024","journal-title":"Hepatol Int"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/gutjnl-2020-321611","article-title":"Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores.","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases.","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"101188","DOI":"10.1016\/j.xcrm.2023.101188","article-title":"Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma.","volume":"4","author":"Allard","year":"2023","journal-title":"Cell Rep Med"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"eadh0831","DOI":"10.1126\/sciadv.adh0831","article-title":"Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC.","volume":"9","author":"Boslem","year":"2023","journal-title":"Sci Adv"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12955-023-02195-x","article-title":"Cross-walk of the Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) and the EuroQol EQ-5D-5L in patients with NASH.","volume":"21","author":"Fishman","year":"2023","journal-title":"Health Qual Life Outcomes"},{"key":"R17-20250504","first-page":"408","article-title":"NASHnext: a noninvasive test for identifying risk of NASH disease progression.","volume":"108","author":"Hoffman","year":"2023","journal-title":"Am Fam Physician"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/KGJU3398","article-title":"Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation.","volume":"27","author":"Bresnahan","year":"2023","journal-title":"Health Technol Assess"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"17548","DOI":"10.1038\/s41598-023-44884-z","article-title":"Exploring immune related gene signatures and mechanisms linking non alcoholic fatty liver disease to atrial fibrillation through transcriptome data analysis.","volume":"13","author":"Wu","year":"2023","journal-title":"Sci Rep"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.dld.2023.09.023","article-title":"Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors.","volume":"56","author":"Lombardi","year":"2023","journal-title":"Dig Liver Dis"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/MEG.0000000000002656","article-title":"Relevance of GLP-1 receptor agonists or SGLT-2 inhibitors on the recruitment for clinical studies in patients with NAFLD.","volume":"36","author":"Holzhey","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejphar.2014.01.040","article-title":"SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.","volume":"727","author":"Yokono","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/dom.14271","article-title":"Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index >\/= 27\u2009kg\/m2.","volume":"23","author":"Danne","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.clinthera.2016.01.017","article-title":"Efficacy and safety of the SGLT2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus stratified according to baseline body mass index: pooled analysis of data from 52-week phase III trials.","volume":"38","author":"Sakai","year":"2016","journal-title":"Clin Ther"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.ajkd.2023.08.016","article-title":"Association of stroke with metabolic dysfunction-associated fatty liver disease with and without CKD.","volume":"83","author":"Li","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2174\/1381612826666200131103018","article-title":"Dysmetabolic hyperferritinemia and dysmetabolic iron overload syndrome (DIOS): two related conditions or different entities?","volume":"26","author":"Rametta","year":"2020","journal-title":"Curr Pharm Des"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"117320","DOI":"10.1016\/j.jep.2023.117320","article-title":"Erchen decoction alleviates the progression of NAFLD by inhibiting lipid accumulation and iron overload through Caveolin-1 signaling.","volume":"319","author":"Deng","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/intimm\/dxx031","article-title":"Hyperferritinemia and inflammation.","volume":"29","author":"Kernan","year":"2017","journal-title":"Int Immunol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00018-023-04966-7","article-title":"Liver endothelial cells in NAFLD and transition to NASH and HCC.","volume":"80","author":"Velliou","year":"2023","journal-title":"Cell Mol Life Sci"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s11883-023-01158-3","article-title":"Mechanisms behind NAFLD: a system genetics perspective.","volume":"25","author":"Pourteymour","year":"2023","journal-title":"Curr Atheroscler Rep"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/19390211.2023.2263788","article-title":"The effects of ginger (zingiber officinale roscoe) on non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: a randomized double-blinded placebo-controlled clinical trial.","volume":"21","author":"Ghoreishi","year":"2023","journal-title":"J Diet Suppl"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s40262-020-00875-1","article-title":"Overview of the clinical pharmacology of ertugliflozin, a novel sodium-glucose cotransporter 2 (SGLT2) inhibitor.","volume":"59","author":"Fediuk","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1097\/QAD.0000000000003562","article-title":"Cardiovascular outcomes among persons with HIV and nonalcoholic fatty liver disease.","volume":"37","author":"Masenga","year":"2023","journal-title":"AIDS"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/dom.14559","article-title":"Empagliflozin and uric acid metabolism in diabetes: a post hoc analysis of the EMPA-REG OUTCOME trial.","volume":"24","author":"Ferreira","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","article-title":"Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease.","volume":"44","author":"Bonnet","year":"2018","journal-title":"Diabetes Metabol"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1038\/s41598-023-32072-y","article-title":"The effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced CKD.","volume":"13","author":"Iwata","year":"2023","journal-title":"Sci Rep"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes.","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41371-018-0134-2","article-title":"Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.","volume":"33","author":"Zhao","year":"2019","journal-title":"J Hum Hypertens"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"1216412","DOI":"10.3389\/fmed.2023.1216412","article-title":"Metabolic characteristics of non-obese and obese metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus and its association with diabetic peripheral neuropathy and diabetic retinopathy.","volume":"10","author":"Dang","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"6661858","DOI":"10.1155\/2023\/6661858","article-title":"Prevalence of GCKR rs1260326 variant in subjects with obesity associated NAFLD and T2DM: a case-control study in South Punjab, Pakistan.","volume":"2023","author":"Nisar","year":"2023","journal-title":"J Obes"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1002\/ptr.7279","article-title":"The effects of co\u2010administration of artichoke leaf extract supplementation with metformin and vitamin E in patients with nonalcoholic fatty liver disease: a randomized clinical trial.","volume":"35","author":"Majnooni","year":"2021","journal-title":"Phytother Res"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1586\/17474124.2015.1007955","article-title":"Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications.","volume":"9","author":"Ballestri","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial.","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"937554","DOI":"10.3389\/fmed.2022.937554","article-title":"A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes.","volume":"9","author":"Doustmohammadian","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial.","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv Ther"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/gut.2005.069153","article-title":"Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study.","volume":"55","author":"Foucher","year":"2006","journal-title":"Gut"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cgh.2023.09.034","article-title":"Embracing change: from NAFLD to MASLD under the steatotic liver disease umbrella.","volume":"22","author":"Noureddin","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"14651","DOI":"10.3390\/ijms241914651","article-title":"Fatty Liver Index (FLI) identifies not only individuals with liver steatosis but also at high cardiometabolic risk.","volume":"24","author":"Carli","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R53-20250504","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13098-023-01164-0","article-title":"Fatty liver index in young adult offspring of women with type 1 diabetes.","volume":"15","author":"Korpijaakko","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"e3736","DOI":"10.1002\/dmrr.3736","article-title":"Simple proxies of insulin resistance identify obese metabolic dysfunction-associated fatty liver disease subjects with advanced liver disease.","volume":"40","author":"Petralli","year":"2023","journal-title":"Diabetes Metab Res Rev"},{"key":"R56-20250504","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.2147\/DDDT.S114932","article-title":"Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date.","volume":"11","author":"Cinti","year":"2017","journal-title":"Drug Design Develop Ther"},{"key":"R57-20250504","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/dom.14385","article-title":"Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: a VERTIS CV substudy.","volume":"23","author":"Lingvay","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"R58-20250504","first-page":"e31404","article-title":"Role of Ertugliflozin in the management of diabetes mellitus.","volume":"14","author":"Totade","year":"2022","journal-title":"Cureus"},{"key":"R59-20250504","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.jhep.2023.09.035","article-title":"Changing from NAFLD to MASLD: the new definition can more accurately identify individuals at higher risk for diabetes.","volume":"80","author":"He","year":"2023","journal-title":"J Hepatol"},{"key":"R60-20250504","first-page":"89","article-title":"The heated debate over NAFLD renaming: an ongoing saga.","volume":"4","author":"Yilmaz","year":"2023","journal-title":"Hepatol Forum"},{"key":"R61-20250504","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1001\/jama.2023.17935","article-title":"Diagnosis and management of nonalcoholic fatty liver disease.","volume":"330","author":"Leung","year":"2023","journal-title":"JAMA"},{"key":"R62-20250504","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.7573\/dic.2020-7-4","article-title":"Ertugliflozin in the treatment of type 2 diabetes mellitus.","volume":"9","author":"Marrs","year":"2020","journal-title":"Drugs Context"},{"key":"R63-20250504","doi-asserted-by":"crossref","first-page":"1284809","DOI":"10.3389\/fendo.2023.1284809","article-title":"Corrigendum: regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis.","volume":"14","author":"Yang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R64-20250504","first-page":"e14974","article-title":"Effect of dapagliflozin on type 2 diabetes mellitus with nonalcoholic fatty liver disease: a single-center survey.","volume":"13","author":"Das","year":"2021","journal-title":"Cureus"},{"key":"R65-20250504","doi-asserted-by":"crossref","first-page":"843","DOI":"10.5009\/gnl220545","article-title":"Nonalcoholic fatty liver disease as a systemic disease and the need for multidisciplinary care.","volume":"17","author":"Yoneda","year":"2023","journal-title":"Gut Liver"},{"key":"R66-20250504","doi-asserted-by":"crossref","first-page":"7728","DOI":"10.3390\/ijms25147728","article-title":"What not to overlook in the management of patients with type 2 diabetes mellitus: the nephrological and hepatological perspectives.","volume":"25","author":"Alfieri","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R67-20250504","doi-asserted-by":"crossref","first-page":"e06","DOI":"10.15420\/ecr.2023.34","article-title":"Treatment options and continuity of care in metabolic-associated fatty liver disease: a multidisciplinary approach.","volume":"19","author":"Lara-Romero","year":"2024","journal-title":"Eur Cardiol Rev"},{"key":"R68-20250504","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4103\/ijem.ijem_377_23","article-title":"SGLT2 inhibitors: paradigm shift from diabetes care to metabolic care \u2013 an Indian perspective.","volume":"28","author":"Kumar","year":"2024","journal-title":"Indian J Endocrinol Metabol"},{"key":"R69-20250504","first-page":"15","article-title":"Paradoxical additional role of SGLT2 inhibitors beyond glycosuria in controlling obesity, NAFLD treatment, pancreatic \u03b2 cell protection besides therapy for diabetes mellitus, CVOT and renoprotection-A minireview.","volume":"4","author":"Kaur","year":"2021","journal-title":"Acta Sci Gastrointestinal Disord"},{"key":"R70-20250504","doi-asserted-by":"crossref","first-page":"bqab157","DOI":"10.1210\/endocr\/bqab157","article-title":"SGLT2 inhibition for cardiovascular diseases, chronic kidney disease, and NAFLD.","volume":"162","author":"Ala","year":"2021","journal-title":"Endocrinology"},{"key":"R71-20250504","first-page":"389","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"384","author":"Heerspink","year":"2021","journal-title":"N Engl J Med"},{"key":"R72-20250504","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.3390\/ijerph16173011","article-title":"Diet and non-alcoholic fatty liver disease: the Mediterranean way.","volume":"16","author":"Abenavoli","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"R73-20250504","doi-asserted-by":"crossref","first-page":"6918","DOI":"10.3390\/molecules28196918","article-title":"Glucosamine improves non-alcoholic fatty liver disease induced by high-fat and high-sugar diet through regulating intestinal barrier function, liver inflammation, and lipid metabolism.","volume":"28","author":"Li","year":"2023","journal-title":"Molecules"},{"key":"R74-20250504","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1097\/MEG.0000000000001656","article-title":"Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients.","volume":"32","author":"Hamurcu Varol","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R75-20250504","doi-asserted-by":"crossref","first-page":"e13464","DOI":"10.1111\/obr.13464","article-title":"The effect of pharmacological treatment and lifestyle modification in patients with nonalcoholic fatty liver disease: an umbrella review of meta-analyses of randomized controlled trials.","volume":"23","author":"Cho","year":"2022","journal-title":"Obes Rev"},{"key":"R76-20250504","doi-asserted-by":"crossref","first-page":"4597246","DOI":"10.1155\/2016\/4597246","article-title":"Nutrition and physical activity in nonalcoholic fatty liver disease.","volume":"2016","author":"Oliveira","year":"2016","journal-title":"J Diabetes Res"},{"key":"R77-20250504","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/tcmj.tcmj_86_20","article-title":"Role of diet and lifestyle modification in the management of nonalcoholic fatty liver disease and type 2 diabetes.","volume":"33","author":"Prabhakar","year":"2021","journal-title":"Tzu Chi Med J"},{"key":"R78-20250504","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3390\/antiox12040833","article-title":"Mediterranean diet improves plasma biomarkers related to oxidative stress and inflammatory process in patients with non-alcoholic fatty liver disease.","volume":"12","author":"Quetglas-Llabr\u00e9s","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"R79-20250504","doi-asserted-by":"crossref","first-page":"100256","DOI":"10.1016\/j.jhepr.2021.100256","article-title":"Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet \u2013 a randomised controlled trial.","volume":"3","author":"Holmer","year":"2021","journal-title":"JHEP Rep"},{"key":"R80-20250504","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s11154-023-09843-z","article-title":"Non-alcoholic fatty liver disease and gut microbial dysbiosis-underlying mechanisms and gut microbiota mediated treatment strategies.","volume":"24","author":"Jayachandran","year":"2023","journal-title":"Rev Endocr Metab Disord"},{"key":"R81-20250504","doi-asserted-by":"crossref","first-page":"14918","DOI":"10.3390\/ijms241914918","article-title":"Prebiotics and probiotics: therapeutic tools for nonalcoholic fatty liver disease.","volume":"24","author":"Mijangos-Trejo","year":"2023","journal-title":"Int J Mol Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:00:50Z","timestamp":1746320450000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":79,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040356","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]}}}